JCO Precision Oncology · 2022 · 48 citations · 36 references
MedicineGeneticsOncologyCancer GeneticsDna RepairMolecular OncologyCancer BiomarkersCancer GenomicsCancer Molecular PathologyDna Repair DefectsMolecular Classification Of TumorsMolecular Tumor ProfilingDna Repair Deficiency SignaturesHomologous Recombination DeficiencyHomologous Recombination Deficiency SignaturesHomologous Recombination RepairMutational Signature AnalysisMutational Signature BiomarkersPoly Adp-ribose Polymerase InhibitorsPoly(adp-ribose) Polymerase Inhibitors
PURPOSE Homologous recombination DNA repair deficiency (HRD) is associated with sensitivity to platinum and poly (ADP-ribose) polymerase inhibitors in certain cancer types, including breast, ovarian, pancreatic, and prostate. In these cancers, BRCA1/ 2 alterations and genomic scar signatures are useful indicators for assessing HRD. However, alterations in other homologous recombination repair (HRR)-related genes and their clinical significance in other cancer types have not been adequately and systematically investigated. METHODS We obtained data sets of all solid tumors in The Cancer Genome Atlas and comprehensively analyzed HRR pathway gene alterations, their loss-of-heterozygosity status, per-sample genomic scar scores, ie, the HRD score and mutational signature 3 ratio, DNA methylation profiles, gene expression profiles, somatic TP53 mutations, sex, and clinical information including chemotherapeutic regimens. RESULTS Biallelic alterations in HRR genes other than BRCA1/ 2 were also associated with elevated genomic scar scores. The association between HRR-related gene alterations and genomic scar scores differed significantly by sex and the presence of somatic TP53 mutations. HRD cases determined by a combination of these indices also showed HRD features in gene expression analysis and were associated with better survival when treated with DNA-damaging agents. CONCLUSION This study provides evidence for the usefulness of HRD analysis in all cancer types, improves chemotherapy decision making and its efficacy in clinical settings, and represents a substantial advancement in precision oncology.
36
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov, Serena Nik‐Zainal, David C. Wedge et al. · Nature · 2013 · 10.1K citations · Full text
Medicine, Cancer Biology, Oncology +14
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Hannah Farmer, Nuala McCabe, Christopher J. Lord et al. · Nature · 2005 · 6.7K citations
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Helen E. Bryant, Niklas Schultz, Huw D. Thomas et al. · Nature · 2005 · 5.2K citations
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
David A. Barbie, Pablo Tamayo, Jesse S. Boehm et al. · Nature · 2009 · 4.2K citations · Full text
International network of cancer genome projects